Advertisement

Clonal cytogenetic abnormalities in donor-derived cells after sex mismatched allogeneic stem cell transplantation

      Highlights

      • Clonal cytogenetic abnormalities (CCA) in donor cells after stem cell transplant (SCT) can be seen in donor-derived cells.
      • CCA may reflect a constitutional abnormality in a donor or may be present in a recipient with or without overt neoplasia.
      • In our cohort, ~1% of the patients had CCA in donor-derived cells.
      • Loss of 7q is the most common somatic CCA, in donor derived cells.
      • Presence of del(7q) in cases without an overt neoplasia appears to be an adverse prognostic factor.

      Abstract

      Clonal cytogenetic abnormalities (CCA) in donor-derived cells after stem cell transplant (SCT) are typically reported in donor-derived cell neoplasms, but CCA also may reflect a constitutional abnormality in the donor or may be present in a recipient without overt hematological malignancy. We reviewed 8515 tests on 2035 patients, who had allogenic sex mismatched SCT and underwent serial cytogenetic analysis between 2006 and 2020 in our institution. A constitutional CCA was observed in 3 patients: inv(10), t(1;5), and t(13;14). A somatic CCA without overt neoplasia was detected in 12 patients: del(7q) (n = 6), del(20q) (n = 3), der(11)t(11;11) (n = 1), t(1;9) (n = 1), dup(6p)(n = 1). In this group, four patients with cytopenia had del(7q), and an association between del(7q) and an adverse overall survival (OS) was observed [HR:5.99; 95%CI 1.23–29.92). Four patients had a donor-derived cell neoplasm: myelodysplastic syndrome (n = 3) and acute myeloid leukemia (n = 1), and all four neoplasms had loss of 7q. In our cohort, ∼1% of the patients (19/2,035) had CCA in donor-derived cells. Balanced constitutional CCA can pose a reproductive risk to donor. Loss of 7q is the most common somatic CCA, in donor-derived cells.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • DeZern A.E.
        • Malcovati L.
        • Ebert B.L
        CHIP, CCUS, and other acronyms: definition, implications, and impact on practice.
        Am Soc Clin Oncol Educ Book. 2019; 39: 400-410
        • Tang G.
        • Medeiros L.J.
        • Wang S.A.
        How I investigate Clonal cytogenetic abnormalities of undetermined significance.
        Int J Lab Hematol. 2018; 40: 385-391
        • Williams L.
        • Doucette K.
        • Karp J.E.
        • Lai C.
        Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome.
        Bone Marrow Transplant. 2021; 56: 1535-1549
        • Engel N.
        • Rovo A.
        • Badoglio M.
        • Labopin M.
        • Basak G.W.
        • Beguin Y.
        • Guyotat D.
        • Ljungman P.
        • Nagler A.
        • Schattenberg A.
        • Schroeder T.
        • Schroyens W.
        • Tischer J.
        • Socie G.
        • Kolb H.J.
        • Tichelli A.
        • Salooja N.
        • Duarte R.F.
        Transplant complications W. European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation.
        Leukemia. 2019; 33: 508-517
        • Kato M.
        • Yamashita T.
        • Suzuki R.
        • Matsumoto K.
        • Nishimori H.
        • Takahashi S.
        • Iwato K.
        • Nakaseko C.
        • Kondo T.
        • Imada K.
        • Kimura F.
        • Ichinohe T.
        • Hashii Y.
        • Kato K.
        • Atsuta Y.
        • Taniguchi S.
        • Fukuda T.
        Donor cell-derived hematological malignancy: a survey by the Japan society for hematopoietic cell transplantation.
        Leukemia. 2016; 30: 1742-1745
        • Consoli C.
        • Leotta S.
        • Tambe L.
        • Di Marco A.L.
        • Avola G.
        • Camuglia M.G.
        • Di Mercurio S.
        • Poidomani M.
        • Milone G.
        Inadvertent transplantation of haematopoietic stem cells carrying constitutional Robertsonian translocation from an apparently normal donor to an AML patient: a case report.
        Bone Marrow Transplant. 2011; 46: 1278-1279
        • Frey N.V.
        • Leid C.E.
        • Nowell P.C.
        • Tomczak E.
        • Strauser H.T.
        • Kasner M.
        • Goldstein S.
        • Loren A.
        • Stadtmauer E.
        • Luger S.
        • Hexner E.
        • Hinkle J.
        • Porter D.L.
        Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor-derived constitutional abnormality.
        Am J Hematol. 2008; 83: 846-849
        • Lang Z.
        • Dinndorf P.
        • Ladisch S.
        • Bayever E.
        • Reaman G.
        Chromosomal transformation in donor cells following allogeneic bone marrow transplantation.
        Bone Marrow Transplant. 2004; 33: 1253-1256
        • Lee S.G.
        • Park T.S.
        • Lim G.
        • Lee K.A.
        • Song J.
        • Choi J.R.
        Constitutional pericentric inversion 9 and hematological disorders: a Korean tertiary institution's experience over eight years.
        Ann Clin Lab Sci. 2010; 40: 273-277
        • Manola K.N.
        • Harhalakis N.
        • Symeonidis A.
        • Rigana H.
        • Stavropoulou C.
        • Karakasis D.
        • Tiniakou M.
        • Baltathakis I.
        • Stamouli M.I.
        • Zoumbos N.
        • Pantelias G.E.
        • Sambani C.
        Constitutional pericentric inversion of chromosome 9 and hematopoietic recovery after allogeneic stem cell transplantation.
        Ann Hematol. 2006; 85: 611-615
        • Manola K.N.
        • Sambani C.
        • Karakasis D.
        • Baltathakis I.
        • Zoumbos N.
        • Symeonidis A.
        Allogeneic stem cell transplantation from donors with mosaic Turner syndrome.
        Bone Marrow Transplant. 2006; 38: 385-386
        • Seo B.Y.
        • Choi H.W.
        • Kang M.G.
        • Cho D.
        • Kee S.J.
        • Kim S.H.
        • Shin J.H.
        • Suh S.P.
        • Ryang D.W.
        • Shin M.G.
        Constitutional chromosomal abnormality identified in a sibling donor after bone marrow stem cell transplantation in a pediatric patient with acute megakaryoblastic leukemia.
        Ann Lab Med. 2015; 35: 162-164
        • Uddin N.
        • Williams M.S.
        • South S.T.
        Constitutional trisomy 8 mosaicism in a healthy bone marrow donor: confirmation of first reported donor origin trisomy 8.
        Am J Hematol. 2010; 85: 974-976
        • Wilk C.M.
        • Manz M.G.
        • Boettcher S.
        Clonal hematopoiesis in hematopoietic stem cell transplantation.
        Curr Opin Hematol. 2021; 28: 94-100
        • Burns S.S.
        • Kapur R.
        Clonal Hematopoiesis of indeterminate potential as a novel risk factor for donor-derived leukemia.
        Stem Cell Rep. 2020; 15: 279-291
        • Liu W.
        • Burger J.A.
        • Xu J.
        • Tang Z.Y.
        • Toruner G.
        • Khanlari M.
        • Medeiros L.J.
        • Tang G.L.
        LPLdeletion is associated with poorer response to ibrutinib-based treatments and overall survival inTP53-deleted chronic lymphocytic leukemia.
        Ann Hematol. 2020; 99: 2343-2349
        • Tang G.
        • Banks H.E.
        • Sargent R.L.
        • Medeiros L.J.
        • Abruzzo L.V.
        Chronic lymphocytic leukemia with t(14;18)(q32;q21).
        Hum Pathol. 2013; 44: 598-605
        • Fickelscher I.
        • Liehr T.
        • Watts K.
        • Bryant V.
        • Barber J.C.
        • Heidemann S.
        • Siebert R.
        • Hertz J.M.
        • Tumer Z.
        • Simon Thomas N
        The variant inv(2)(p11.2q13) is a genuinely recurrent rearrangement but displays some breakpoint heterogeneity.
        Am J Hum Genet. 2007; 81: 847-856
        • Morel F.
        • Laudier B.
        • Guerif F.
        • Couet M.L.
        • Royere D.
        • Roux C.
        • Bresson J.L.
        • Amice V.
        • De Braekeleer M.
        • Douet-Guilbert N.
        Meiotic segregation analysis in spermatozoa of pericentric inversion carriers using fluorescence in-situ hybridization.
        Hum Reprod. 2007; 22: 136-141
        • Gardner R.
        • Amor D.J
        Gardner and sutherland's chromosome abnormalities and genetic counseling.
        Oxford University Press, 2018: 69-112
        • Gardner R.
        • Amor D.J
        Gardner and sutherland's chromosome abnormalities and genetic counseling.
        Oxford University Press, 2018: 142-157
        • He J.
        • Abdel-Wahab O.
        • Nahas M.K.
        • Wang K.
        • Rampal R.K.
        • Intlekofer A.M.
        • Patel J.
        • Krivstov A.
        • Frampton G.M.
        • Young L.E.
        • Zhong S.
        • Bailey M.
        • White J.R.
        • Roels S.
        • Deffenbaugh J.
        • Fichtenholtz A.
        • Brennan T.
        • Rosenzweig M.
        • Pelak K.
        • Knapp K.M.
        • Brennan K.W.
        • Donahue A.L.
        • Young G.
        • Garcia L.
        • Beckstrom S.T.
        • Zhao M.
        • White E.
        • Banning V.
        • Buell J.
        • Iwanik K.
        • Ross J.S.
        • Morosini D.
        • Younes A.
        • Hanash A.M.
        • Paietta E.
        • Roberts K.
        • Mullighan C.
        • Dogan A.
        • Armstrong S.A.
        • Mughal T.
        • Vergilio J.A.
        • Labrecque E.
        • Erlich R.
        • Vietz C.
        • Yelensky R.
        • Stephens P.J.
        • Miller V.A.
        • van den Brink M.R.
        • Otto G.A.
        • Lipson D.
        • Levine R.L.
        Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.
        Blood. 2016; 127: 3004-3014
        • Yin C.C.
        • Peng J.
        • Li Y.
        • Shamanna R.K.
        • Muzzafar T.
        • DiNardo C.
        • Khoury J.D.
        • Li S.Y.
        • Medeiros L.J.
        • Wang S.A.
        • Tang G.L.
        Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies.
        Mod Pathol. 2015; 28: 1014-1022
        • Ravindran A.
        • He R.
        • Ketterling R.P.
        • Jawad M.D.
        • Chen D.
        • Oliveira J.L.
        • et al.
        The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm.
        Blood Cancer J. 2020; 10
        • Hasserjian R.
        • Orazi A.
        • Brunning R.D.
        • Germing U.
        • Le Beau M.M.
        • Porwit A.
        • et al.
        Myelodysplastic syndoromes: overview.
        (editor.)in: Swerdlow S.H. Campo E. Harris N.L. Jaffe E.S. Pileri S.A. Stein H. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer (IARC), 2017: 98-106
        • Hammond D.
        • Loghavi S.
        Clonal haematopoiesis of emerging significance.
        Pathology. 2021; 53: 300-311
        • Newell L.F.
        • Williams T.
        • Liu J.
        • Yu Y.
        • Chen Y.
        • Booth G.C.
        • et al.
        Engrafted donor-derived clonal hematopoiesis after allogenic hematopoietic cell transplantation is associated with chronic graft-versus-host disease requiring immunosuppressive therapy, but no adverse impact on overall survival or relapse.
        Transplant Cell Ther. 2021; 27: 662